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Abstract Nanotechnology represents a new and enabling
platform that promises to provide a range of innovative
technologies for biological applications. ZnO nanoparticles
of controlled size were synthesized, and their cytotoxicity
toward different human immune cells evaluated. A differ-
ential cytotoxic response between human immune cell
subsets was observed, with lymphocytes being the most
resistant and monocytes being the most susceptible to ZnO
nanoparticle-induced toxicity. Signiﬁcant differences were
also observed between previously activated memory lym-
phocytes and naive lymphocytes, indicating a relationship
between cell-cycle potential and nanoparticle susceptibil-
ity. Mechanisms of toxicity involve the generation of
reactive oxygen species, with monocytes displaying the
highest levels, and the degree of cytotoxicity dependent on
the extent of nanoparticle interactions with cellular mem-
branes. An inverse relationship between nanoparticle size
and cytotoxicity, as well as nanoparticle size and reactive
oxygen species production was observed. In addition, ZnO
nanoparticles induce the production of the proinﬂammatory
cytokines, IFN-c, TNF-a, and IL-12, at concentrations
below those causing appreciable cell death. Collectively,
these results underscore the need for careful evaluation of
ZnO nanoparticle effects across a spectrum of relevant cell
types when considering their use for potential new nano-
technology-based biological applications.
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Introduction
Nanotechnology permits the manipulation of matter at the
nanometer scale, which enables precision engineering to
control nanomaterial physiochemical properties as well as
their interactions with biological systems. It is the altera-
tions in electrical, magnetic, structural, morphological,
chemical, and physical properties of nanomaterials, which
are comparable in size to naturally occurring biomolecules,
that makes them particularly attractive for pioneering
applications in technological and biological applications
[1–4]. Nanomaterials comprised of ZnO have received
considerable attention in recent years because of their
potential use in electronic and industrial applications aris-
ing from their wide band gap (3.36 eV) semiconductor
properties [3]. From a biological perspective, nanoscale
ZnO materials are already being used in the cosmetic and
sunscreen industry due to their transparency and ability to
reﬂect, scatter, and absorb UV radiation, and as food
additives [5, 6]. ZnO nanomaterials are also being con-
sidered for use in next-generation biological applications
including antimicrobial agents, drug delivery, bioimag-
ing probes, and cancer treatment [7–10]. Although bulk
(micron-sized) ZnO is generally recognized as a GRAS
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exhibit appreciable cellular toxicity when reduced to the
nanoscale [11]. Recent toxicological studies using certain
engineered nanoparticles (NPs) have conﬁrmed the poten-
tially harmful effects due to their high surface area, unique
physiochemical properties, and increased reactivity of the
material’s surface [11, 12]. This has led to the term,
nanotoxicology, which describes the relationship between
nanoparticle physiochemical properties and toxicological
effects on living cells and biological systems.
In this regard, several recent reports have demonstrated
the toxicity of metal-oxide NPs to both prokaryotic and
eukaryotic cellular systems [7, 10, 13–16], while the bulk
micron-sized materials remain nontoxic. The majority of
eukaryotic studies speciﬁc to ZnO NPs, however, have
relied heavily on the use of immortalized cells lines, which
are recognized to display altered sensitivities to foreign
materials/chemicals due to alterations in metabolic pro-
cesses and major genetic instabilities. To date, only limited
studies have evaluated the toxicity of ZnO NPs on normal
primary human cells and their potential immunomodulatory
effects. Even more challenging is the fact that the cytotoxic
response is very different between cell types and nanoma-
terial systems, making it difﬁcult to develop predictive
models without detailed and systematic investigations.
Recent reports demonstrate that ZnO NPs display differ-
ential toxicity towards primary human cells depending upon
theirproliferationpotential,withnormalTlymphocytesthat
are stimulated to divide by signaling through the T cell
receptor displaying signiﬁcantly greater toxicity than qui-
escent nonproliferating cells of identical lineage [13]. When
these studies were extended to immortalized T leukemic
and lymphoma cells using identical ZnO NPs, an even
greater sensitivity to NP-induced toxicity was observed
(*33-fold) [13]. Thus, susceptibility to NP-induced cyto-
toxicity appears to be related to the proliferative capacity of
the cell and may also be affected by other physiologically
relevant parameters, including cell-NP electrostatic inter-
actions and inherent differences in cellular endocytic/phag-
ocytic processes that facilitate NP uptake. These variations
in cytotoxic response indicate that a more detailed and
carefully controlled evaluation of ZnO NP effects on mul-
tiple types of normal human cells is needed to better
understand the biological consequences of NP exposure. In
addition, it is increasingly being recognized that toxicity
depends on nanomaterial characteristics including size,
shape, and electrostatic charge, as well as materials com-
position [7, 10, 17, 18]. In this study, the evaluation of
size-controlled ZnO NPs and their resulting toxicity on
different cells comprising the human immune system is
explored. In addition, mechanisms underlying the differ-
ential toxicity response are investigated, as well as effects
ofZnONPs toinduceproinﬂammatorycytokineexpression.
Experimental
Preparation and Characterization of ZnO Nanoparticles
ZnO NPs utilized in all experiments were synthesized in
diethylene glycol (DEG) via forced hydrolysis of zinc
acetate [14]. In brief, zinc acetate was dissolved in DEG,
and then nanopure water was added under magnetic stir-
ring. Subsequently, the system was heated at 160  C under
reﬂux for 90 min. After cooling, the resulting product was
removed from DEG via centrifugation, and washed with
ethanol several times before drying for 24 h at 50  C,
resulting in a powder sample. The sample crystal phase,
crystallite size, and morphology were characterized via
X-ray diffraction (XRD) and transmission electron micro-
scopy (TEM) as previously described [13, 14]. The NPs
were then weighed and reconstituted in phosphate buffered
saline (PBS) solution to the desired stock concentration.
After reconstitution, NPs were sonicated for 10 min and
immediately vortexed prior to addition to cell cultures.
Isolation of Peripheral Blood Mononuclear Cells
For isolation of PBMC (peripheral blood mononuclear
cells) and immune cell subsets, written informed consent
was obtained from all blood donors. The University Insti-
tutional Review Board approved this study. PBMC were
obtained via Ficoll-Hypaque (Histopaque-1077, Sigma,
St Louis, MO) gradient centrifugation using heparinized
phlebotomy samples [19]. After removal of the leukocyte
layer, cells were washed three times with Hank’s buffer
(Sigma, St. Louis, MO) and resuspended at a ﬁnal con-
centration of 1 9 10
6 cells/mL in RPMI-1640 (Sigma),
containing 10% fetal bovine serum (FBS) and cultured at
37  C and 5% CO2.
Isolation and Culture of Primary CD14
? Monocytes
and CD4
? T cells
PBMC were obtained by Ficoll-Hypaque density centrifu-
gation as described above, and CD14
? cells isolated from
the mixed cell suspension. Negative immunomagnetic
selection was performed according to the manufacturer’s
protocol using a cocktail of antibodies directed against
CD2, CD3, CD16, CD19, CD20, CD56, CD66b, CD123,
and glycophorin A (StemCell Technologies, Vancouver,
BC). For optimal cell recovery, PBMC were ﬁrst blocked
with anti-human CD32 (Fcc RII) blocker reagent before
labeling with the antibody cocktail. Puriﬁed CD14
?
monocytes populations were typically of[92% purity and
[97% viable as assessed by ﬂow cytometry and cultured in
RPMI/10% FBS at 5 9 10
5 cells/mL in 96-well plates at
37 C and 5% CO2.
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? T cells were puriﬁed from PBMC using negative
immunomagnetic selection per manufacturer’s instructions,
and a cocktail of antibodies directed against CD8, CD14,
CD16, CD19, CD56, and glycophorin A surface markers
(StemCell Technologies). Unlabeled T cells were collected
(typically [97% purity and [95% viable as assessed by
ﬂow cytometry) and subsequently cultured in RPMI/10%
FBS at a ﬁnal concentration of 1 9 10
6 cells/mL.
Flow Cytometry
Methods of immunoﬂuorescent staining and ﬂow cyto-
metric analysis were performed as previously described
[19] using a four-color Epics XL ﬂow cytometer (Beckman
Coulter, Miami, FL). Cells were stained with ﬂuorescently
labeled antibodies (Beckman Coulter) for 30 min at 4  C,
washed two times, and immediately analyzed. Ten thou-
sand events gated on the parameter of size (forward scatter,
or FS) and granularity (side scatter, or SSC) were analyzed,
and expression of the percentage of positively staining cells
and the mean ﬂuorescence intensity (MFI) determined by
comparisons to isotype controls. Appropriate concentra-
tions of each antibody were determined by titration for
optimal staining prior to experimental use. In PBMC cul-
tures, individual cell types were distinguished from one
another based on differential antibody staining and on FS
and SSC properties. T cells were deﬁned as CD3
?;
T helper cells deﬁned as CD3
?, CD4
?; naive T cells
deﬁned as CD3
?, CD45RA
?; memory T cells deﬁned as
CD3
?, CD45RO; B cells deﬁned as CD19
?, CD3; NK cells
deﬁned as CD56
?, CD16
?, CD3
-; and monocytes deﬁned
as CD14
?, CD3
-. To prevent indiscriminate antibody
staining of monocytes via Fc receptors, 100 lL of heat-
inactivated human AB serum was added to experimental
samples immediately prior to staining.
Cell Viability Assays
Cell viability following NP treatment was assessed using
two different assays. In the ﬁrst assay, cell subsets were
identiﬁed using ﬂuorescently labeled antibodies, and
viability was determined by staining with 50 lg/mL of
propidium iodide (PI) to monitor losses in cell membrane
integrity. Fluorescent CountBright counting beads (Invit-
rogen, Carlsbad, CA) were added to samples to enable
determinations of absolute cell numbers, and ﬂow cytom-
etry was used to evaluate changes in PI staining and to
quantify cell death. NPs were excluded from the analysis
based on the absence of ﬂuorescence signal and light FS
and SSC characteristics.
The second viability assay employed the ﬂuorogenic
redox indicator dye, Alamar Blue. This dye becomes
ﬂuorescent upon reduction by mitochondrial enzymes in
metabolically active cells. Cell populations were seeded
into 96-well plates at 5 9 10
5 cells/mL, treated with ZnO
NP for 18 h, and 20 lL of Alamar Blue added to cultures
for an additional 6 h. Changes in ﬂuorescence were eval-
uated spectrophotometrically using excitation/emission at
530/590 nm.
ROS Detection
To assay for NP-induced reactive oxygen species (ROS)
production, cells were ﬁrst obtained from whole blood
treated with an ammonium chloride lysing solution (1.5 M
NH4Cl, 0.1 M NaHCO3, 0.01 EDTA) to lyse red blood
cells, and centrifuged for 10 min at 4  C to remove
erythrocytic debris. The white blood cells were then
resuspended in phenol red-free RPMI to a ﬁnal concen-
tration of 1 9 10
6 cells/mL and incubated with ZnO NPs
for 6 to 20 h. Cells were subsequently loaded with 5 lMo f
the oxidation-sensitive dye, 20,70-dichloroﬂuorescein diac-
etate (DCFH-DA, Invitrogen, Carlsbad, CA) for 20 min.
Production of the oxidation product was evaluated using
ﬂow cytometry as previously described [20]. White blood
cell populations (i.e., CD3
? T cells and CD14
?, CD3
-
monocytes) present in the samples were simultaneously
evaluated based on FS and SSC gating and staining with
appropriate ﬂuorescently labeled antibodies. As a positive
control for ROS production, control cells were loaded with
DCFH-DA dye and activated with PMA (25 ng/mL) for
1 h. For studies described in Fig. 8, ROS production was
evaluated in PBMC treated with differently sized ZnO NPs
using a ﬂuorescent microplate reader as previously
described [21, 22]. Experimental methodology, including
the use of the DCFH-DA dye to indicate ROS generation,
was identical as described above.
To determine the role of ROS in NP-induced cell death,
puriﬁed primary CD4
? T cells and monocytes were seeded
in a 96-well plate at 5 9 10
5 cells/mL and pretreated with
5 mM of the ROS scavenger, N-acetyl cysteine (NAC,
Sigma) for 4–6 h. Cultures were then treated with various
concentrations of ZnO NP for 24 h, and viability was
determined using the Alamar Blue cytotoxicity assay and a
ﬂuorescent microplate reader.
Cytokine Analysis
ToinvestigatetheeffectofZnONPsoncytokineproduction,
an ELISA (enzyme linked immunosorbent assay) was used.
For determination of IFN-c and TNF-a production, freshly
isolated PBMC were cultured at 1 9 10
6 cells/mL and
treated with varying concentrations of 8nm ZnO NPs (0.05,
0.1and0.2 mM)for38 h.FordeterminationofIL-12levels,
PBMC cultures were either left untreated or pretreated
with 1,000 U/mL of IFN-c (Peprotech, Rocky Hill, NJ), to
Nanoscale Res Lett (2009) 4:1409–1420 1411
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with ZnO NPs for 24 h. After NP treatment, cell-free
supernatants were harvested via successive 10-min centrif-
ugations(2,000 rpm,7,000 rpmand13,000 rpm)andstored
at -80  C until analysis. ELISA was performed by the
UMABCytokineCoreLaboratory(Baltimore,MD),withall
samples analyzed in triplicate.
Statistical Analyses
All data were analyzed using SAS, Inc. software (Cary,
NC). Data for Figs. 3, 4, and 6 were analyzed using repe-
ated measures of variance with post hoc comparisons to
allow within-subject variation to be separated from
between-subject variation. Data for Figs. 5, 7 and 8 were
analyzed using a two-way analysis of variance (ANOVA).
In all cases, signiﬁcance levels were deﬁned as p\0.05.
Results and Discussion
Synthesis and Size Control of ZnO Nanoparticles
To evaluate the relationship between NP size and cytotoxic
properties on various types of immune cells, ZnO NPs
(4–20 nm) were synthesized by modifying the hydrolysis
molar ratio of water to zinc acetate. Transmission electron
microscopy (TEM) measurements shown in Fig. 1a–d
demonstrate that the use of hydrolysis ratios (water:zinc
acetate) of 2.4, 6.1, 12.2, and 24.4 yields NPs with average
diameters of 4–8, 13, and 20 nm, respectively. The 4-nm
NP produced by this synthesis method is roughly spherical
in morphology, while NPs C8 nm acquire a rod-shaped
morphology. The corresponding particle size histogram
(Fig. 1e) shows that all of the ZnO samples have a narrow
size distribution. The X-ray diffraction (XRD) patterns
shown in Fig. 2 indicate that all of the ZnO samples are
well-indexed to the pure wurtzite crystallite phase of ZnO,
demonstrating that the sample is comprised of ZnO nano-
crystals. Furthermore, the average crystallite sizes esti-
mated using the peak widths (full width at half maximum)
of the XRD patterns agree well with TEM results for both
size and shape, where the average aspect ratio of NPs
[8 nm increases up to 2 (Fig. 2 inset).
T and B Lymphocytes are More Resistant to NP
Toxicity Compared to Monocytes and NK Cells
Previous studies from our laboratory have determined that
rapidly dividing cancerous T cells are more susceptible to
ZnO NP toxicity than normal quiescent T cells [13]. These
ﬁndings were extended to determine whether NP toxicity
might also vary between different types of normal cells
comprising the human immune system including T cells, B
cells, natural killer (NK) cells, and monocytes. For these
studies, freshly isolated peripheral blood mononuclear cell
(PBMC) preparations were used, since all of the desired
cell types for study are present in the same culture allowing
for a well-controlled and uniform NP exposure. Following
24 h NP (8-nm) treatment, the various cell types were
identiﬁed by staining with antibodies speciﬁc for T, B, NK
or monocyte surface markers, and NP-induced cytotoxicity
was assessed using propidium iodide (PI), which is a red
ﬂuorescent nuclear stain that selectively enters cells with
disrupted plasma membranes. As shown in Fig. 3a, dif-
ferences in NP-induced cytotoxicity were apparent with
lymphocytes (CD3
? T cells, CD4
? T cells, and B cells)
displaying the most resistance. All of these lymphocyte
populations displayed similar IC50 values (*5.0 mM),
with no signiﬁcant difference observed between them at
any NP concentration evaluated. In contrast, NK cells were
substantially more sensitive to NP-induced cytotoxicity,
Fig. 1 TEM images of ZnO nanoparticle samples made using the
hydrolysismolarratio(water:zincacetate)of2.4(panela),6.1(panelb),
12.2 (panel c), and 24.4 (panel d). Panel (e) shows the corresponding
size distribution of the samples shown in panel a (4 nm), panel b
(8 nm), panel c (13 nm) and panel d (20 nm). Panel (e) shows a
histogram obtained from TEM data demonstrating particle size
distribution
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ences were detected between NK cells and B and T lym-
phocytes at 1–5 mM NP concentrations (e.g., p = 0.003 at
1 mM, p = 0.0002 at 2.5 mM, p = 0.002 at 5 mM, and
p = 0.05; NK cells vs. CD3
? T cells at 10 mM NP). Most
striking is the increased NP-induced cytotoxicity observed
in monocytes, with [50% of the monocytes killed at the
lowest NP concentration tested (0.5 mM). Statistically
signiﬁcant differences were observed between monocytes
and NK cells (0.5 mM and 1 mM; p = 0.0002 and
p = 0.0008, respectively), and monocytes compared to
T and B lymphocytes (p\0.0001 for both cell types at
both concentrations tested).
Because adherent monocytes appear considerably more
susceptible to NP-induced cytotoxicity compared to other
immune cell subsets, additional experiments were per-
formed using puriﬁed monocytes and lower concentrations
of NP, to more accurately determine the IC50 value. In these
experiments, monocytes were treated with varying con-
centrations of ZnO NPs, and viability was evaluated using
the ﬂuorogenic redox Alamar Blue cytotoxicity assay. In
agreement with monocyte data obtained from PBMC cul-
tures, an IC50 of *0.30 mM was observed (Fig. 3b). The
Alamar Blue cytotoxicity assay was also used to conﬁrm the
IC50 usingpuriﬁed CD4
? Tcells, and a similar IC50 value of
*5.4 was observed (data not shown). As previously
reported by our laboratory [13, 14, 23], control experiments
using bulk micron-sized ZnO powder showed no appre-
ciable toxicity effect at any of the concentrations tested
(e.g., viability with bulk ZnO: 96 ± 3% at 1 mM, 93 ± 3%
at 10 mM), demonstrating that toxicity is limited to nano-
scale ZnO. In addition, no appreciable toxicity was
observed using NP-free supernatants (e.g., 98% viability
with NP-free supernatant equivalent to 1–10 mM), indi-
cating that the toxicity is likely not due to dissolved Zn ions
from NP preparations.
Fig. 2 X-ray diffraction h-2h scans of powder samples of various
sizes of ZnO nanoparticles recorded in air at room temperature. The
X-ray source used was Cu Ka with an effective wavelength
k = 1.5418 A ˚. The peak widths are inversely related to the crystallite
sizes according to the Scherrer relation, enabling the XRD patterns to
demonstrate the change in particle size. The stick pattern from
reference data for wurtzite ZnO is shown along the x-axis (repre-
sented by the solid squares) and fully indexes the experimental data.
The inset shows the relationship between average crystallite size (L)
and average aspect ratio (AR) of several samples, prepared using the
synthesis method employed in this work, as determined by XRD. AR
was calculated from the widths of the (100) and (002) XRD peaks,
and excludes data for 4-nm samples due to the amount of peak
overlap
Fig. 3 Differential cytotoxic effects of ZnO NPs on human immune
cell subsets. a PBMC were treated with varying concentrations
(0, 0.5, 1, 2.5, 5, and 10 mM) of 8-nm ZnO NPs for 24 h and viability
of CD3
? T cells, CD4
? T cells, B cells, NK cells, and monocytes
present in same PBMC cultures determined by monitoring PI uptake
using ﬂow cytometry. Data from three independent experiments are
presented with error bars depicting standard error (SE). Asterisks
denote statistically signiﬁcant (p\0.05) differences between CD3
?
T cells, B cells, NK cells, and monocytes at indicated NP
concentrations as determined using a repeated measures ANOVA.
b ZnO NP toxicity on puriﬁed human primary monocytes. Puriﬁed
human peripheral blood CD14
? monocytes were treated with varying
concentrations of ZnO NPs (0.0625–1 mM), and viability assessed
using the Alamar Blue cytotoxicity assay with error bars representing
SE, (n = 4). The IC50 was determined using nonlinear regression
analysis
Nanoscale Res Lett (2009) 4:1409–1420 1413
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considerably more susceptible to NP-induced cytotoxicity
than other immune cell types tested, it is important to note
that these differences may be related to distinctions in cell-
culture conditions. While T cells, B cells, and NK cells
grow as suspension cultures, cultured monocytes grow as
an adherent monolayer. These differences in growth char-
acteristics may act to increase the effective ZnO NP con-
centration in adherent cultures. It is also plausible that the
inherently greater capacity of adherent monocytes to
phagocytose foreign materials, including NPs, may
underlie their greater sensitivity, and the inherent cytolytic
activity of NK cells against foreign pathogens, and altered
self-cells may contribute to their greater sensitivity com-
pared to lymphocyte populations. To address these possi-
bilities, future experiments involving three-dimensional
cell culture systems and those evaluating the extent to
which phagocytic/endocytic mechanisms contribute to cell-
type differences are needed. Nevertheless, given the vari-
able susceptibilities of different immune cell types to ZnO
NPs, it seems clear that careful analysis of in vitro cellular
systems, followed by appropriate in vivo studies, is nec-
essary to provide thorough and possibly predictive
screening data regarding the relative toxicity and immu-
nomodulatory effects of ZnO NP.
Memory and Naive T cells Differ in Cytotoxic
Response to ZnO NP
Our previous ﬁndings that ZnO NP toxicity is dependent on
the cell activation status, with quiescent T cells being more
resistant to ZnO NP-induced cytotoxicity than identical
cells activated to divide via stimulation through the T cell
receptor [13], led us to evaluate whether ‘‘memory’’ T cells
display greater sensitivity to ZnO NPs than ‘‘naive’’ T
cells. During an immune response, the activation of T cells
to a speciﬁc antigen found on a pathogen results in a cas-
cade of intracellular signaling events, and to the differen-
tiation of naive T cells into memory cells. Once memory
cells have formed, they can become activated to proliferate
much more readily upon subsequent exposure to the ori-
ginal antigen [24]. This occurs because memory T cells
require lower activation signals/thresholds to proliferate,
which is due, at least in part, to alterations in intracellular
calcium mobilization and calcium-dependent signaling
processes [25, 26].
To assess potential susceptibilities of naive and memory
T cell populations to ZnO NPs in a well-controlled envi-
ronment, PBMC (which contained both naive and memory
T cells) were treated with 8-nm ZnO NPs for 22–24 h, with
the viability assessed by PI uptake using ﬂow cytometry.
Naive CD3
? T cells (CD45RA
?, CD3
?) were identiﬁed
based on the expression of the CD45RA surface marker,
while memory T cells (CD45RO
?, CD3
?) were identiﬁed
based on expression of the distinguishing CD45RO surface
marker [26, 27]. Cytotoxic responses were then compared
to bulk cultures of CD3
? T cells containing both naive and
memory cells from the same blood donor. As shown in
Fig. 4, memory T cells displayed signiﬁcantly greater
sensitivity to NP toxicity than either naive T cells or bulk
cultures of CD3
? T cells (p = 0.0044 and p = 0.0244) at
10 mM ZnO NP concentration. Naive T cells appeared
more resistant than CD3
? T cells, although statistically
signiﬁcant differences were not observed (p = 0.08).
These results demonstrate that even subsets of T cells show
measureable differences in cytotoxic response to ZnO NP,
which appears related to their activation threshold and/or
proliferation potential.
ZnO NP Induce ROS Production in Monocytes
and T Cells
Reactive oxygen species (ROS) are produced by cells as
part of normal metabolic processes. However, in situations
where ROS production exceeds the cell’s antioxidant
capability, cell death can occur by interfering with normal
physiological processes and the modiﬁcation of cellular
biomolecules [28]. Recently, several types of nanomaterials
including quantum dots and metal-oxide NPs have been
shown to induce intracellular generation of ROS [13, 15, 16,
29], although only limited studies have evaluated the ability
of ZnO NPs to induce ROS in normal/nontransformed
Fig. 4 Differential ZnO NP cytotoxicity between naive and memory
T cells. Human peripheral blood PBMC were left untreated or treated
with 10 mM ZnO NPs (8-nm) for 22–24 h and viability determined
by monitoring PI uptake using ﬂow cytometry. T cells were deﬁned as
CD3
?, naive T cells as CD3
?, CD45RA
?, and memory T cells as
CD3
?, CD45RO
?. Data from three independent experiments are
presented and error bars depict SE. Asterisks denote statistically
signiﬁcant differences (p\0.05) between NP treatment groups using
as a one-way repeated measures ANOVA
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of ZnO NP-induced cellular toxicity in normal immune cell
populations, studies compared ROS production between
primary monocytes and T cells. Based on the differing
sensitivities of these two cell populations, two different
concentrations of 8-nm-sized ZnO NPs were used (i.e.,
1 mM and 5 mM). ROS generation was evaluated using the
widely used cell permeable DCFH-DA dye to measure
oxidative stress in cells. Following diffusion across the
plasma membrane, this dye can be subsequently oxidatively
modiﬁed into a highly ﬂuorescent derivative by ROS,
including superoxide anion and hydrogen peroxide in cel-
lular environments containing cofactors [30–33]. Studies
were performed using mixed PBMC cultures to allow for
identical NP-treatment conditions, and cell identiﬁcation
was determined by staining with ﬂuorescently labeled
antibodies directed toward the CD3 and CD14 surface
markers. Flow cytometry was then used to simultaneously
identify monocytes and T cells, as well as their corre-
sponding level of ROS production at both early and
extended exposure times. As shown in Fig. 5, there was a
modest amount of ROS produced in monocytes treated with
1 mM NP (19% ROS producing cells) as early as 6 h post
ZnO NP exposure, yet no detectable ROS was observed in
T cells at the corresponding NP concentration and time
point. However, at 20 h of treatment, appreciable ROS
production was observable in T cells (*38% ROS pro-
ducing cells at 5 mM ZnO NP), yet no residual cell-asso-
ciated ROS signal was observed in monocytes as nearly
complete cell death was noted. These results indicate that
ZnO NPs are capable of inducing intracellular ROS in both
cell types, although ROS production in monocytes occurs
considerably earlier than for T cells, which may mecha-
nistically underlie their greater sensitivity to ZnO NPs.
ROS Quenchers Rescue Primary Monocytes
and T Cells from ZnO NP-Induced Cytotoxicity
Experiments were then performed to determine the causal
role of NP-induced ROS as a major mechanism of toxicity.
Puriﬁed human CD14
? monocytes and CD4
? T cells were
pretreated with N-acetyl cysteine (NAC), a well-known
ROS quenching agent [34], prior to ZnO NP exposure.
Following 24 h of ZnO NP treatment, cell viability was
assessed using the Alamar Blue cytotoxicity assay. Figure 6
reveals that 5 mM NAC signiﬁcantly protects both mono-
cytes and CD4
? T cells against cell death (p = 0.0001 and
p = 0.0481, respectively), and implicates ROS formation
Fig. 5 Kinetics and magnitude
of ROS production in T cell and
monocyte populations. Freshly
isolated PBMC were treated
with either 1 or 5 mM of 8-nm-
sized ZnO NPs for 6 to 20 h.
Following NP exposure, cells
were loaded with the oxidation-
sensitive DCFH-DA probe.
Flow cytometry was then used
to simultaneously evaluate ROS
production and distinguish T
cells and monocytes present in
PBMC cultures by staining with
ﬂuorescently labeled CD3 and
CD14 antibodies (a, c), n = 3.
Parallel experiments were used
to evaluate effects of NP
treatment on cell viability by
PI uptake and ﬂow cytometry
(b, d), n = 3. Error bars depict
standard error
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mary immune cells.
ZnO NP Preferentially Associate with Monocytes
Compared to Lymphocytes
Experiments were performed to gain insights into the
mechanisms underlying the greater susceptibility of
monocytes to NP-induced cytotoxicity, by evaluating the
extent towhich NPspreferentiallyassociatewith thesecells.
FITC-encapsulated ZnO NPs (FITC-ZnO NPs) were pre-
pared as previously described by our group [23], and their
ﬂuorescence properties were used to monitor the extent to
which they physically and stably associate with cells.
Freshly isolated PBMC were treated with 5 mM FITC-ZnO
NP, or left untreated, and multi-color ﬂow cytometry was
used to simultaneous identify monocytes and lymphocyte
populations present in the PBMC culture, as well as the
relative increase in the FITC-NP signal. As shown in
Table 1, all immune cell types evaluated showed a strong
association with NPs, with 78–98% of cells displaying at
least some level of positive FITC ﬂuorescence compared to
control cells cultured in the absence of NPs. However, a
9.3–13.7-fold increase in the number of NP associating with
any given monocyte compared to individual T or B lym-
phocytes was observed, as indicated by changes in mean
ﬂuorescence intensity (MFI) values. These results demon-
strate that ZnO NPs preferentially associate with monocytes
(MFI: 131.2), compared to lymphocyte subpopulations
(MFI: 9.84 for CD3
? T cells, MFI: 14.1 for CD4
? T cells
and MFI: 9.61 for B cells). The greater NP association with
monocytes may arise through either extracellular mem-
brane-NPinteractionsorintracellularNPuptake,aswehave
previously reported the ability of these same FITC-encap-
sulated NPs to be intracellularly localized in the human
Jurkat T cell line using confocal microscopy [23].
Fig. 6 Quenching of ROS rescues T cells and monocytes from ZnO
NP-induced cytotoxicity. Puriﬁed peripheral blood CD14
? monocytes
(C96%purity) and CD4
? T cells (C95% purity) were pretreated for
4–6 h with 5 mM N-acetyl cysteine (NAC) or vehicle control and
then subsequently cultured with 8-nm-sized ZnO NPs, or left
untreated for 24 hr. Viability was assessed using the Alamar Blue
cytotoxicity assay. a Puriﬁed monocytes treated with 0.125 mM ZnO
NPs ± 5 mM NAC, n = 3. b Isolated CD4
? T cells treated with
5 mM ZnO NPs ± 5 mM NAC, n = 3. Asterisks denote statistically
signiﬁcant differences (p\0.05) as analyzed using a 2-way ANOVA
and error bars depict SE
Table 1 NP association with immune cell subsets
Control (%/MFI)
a ? FITC-NP (%/MFI)
b
CD3
? T cells 1.79% ± 3.1%/1.15 ± 1.27 84.2% ± 4.1%/9.84 ± 3.23
CD4
? T cells 1.61% ± 2.6%/1.23 ± 2.98 82.5% ± 5.9%/14.1 ± 7.21
CD19
? B cells 2.0% ± 1.9%/2.85 ± 4.39 78.1% ± 3.1%/9.61 ± 5.11
CD14
? Monocytes 1.7% ± 3.4%/5.80 ± 4.82 98.0% ± 2.5%/131.2 ± 20.11
Freshly isolated PBMC were left untreated or exposed to 5 mM FITC-encapsulated ZnO NPs for 15 h. The cell mixture was then stained with
ﬂuorescently labeled CD3, CD4, CD19, CD14 antibodies to identify subsets, washed to remove excess antibody and unbound NPs, and the level
of NP association determined based on FITC ﬂuorescent signal using ﬂow cytometry. Data were obtained by gating on 10,000 events, n = 3
a Values shown represent the background autoﬂuorescence signal for control cells (percent FITC positive cells/mean ﬂuorescent intensity
(MFI) ± SE)
b The percentage of FITC positive cells and MFI for cells treated with FITC-doped ZnO NP
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Production
To evaluate the relationship between ZnO NP size and its
toxic potential, three different sizes of ZnO NPs (4, 13, and
20 nm) were concurrently evaluated using primary human
CD4
? T cells as a model system. Experiments shown in
Fig. 7a were performed using a NP concentration of 5 mM,
given the observed IC50 value for T cells observed above.
These experiments demonstrate that signiﬁcantly greater
cytotoxicity was observed with 4-nm NPs (80.0% ± 2.0%),
compared to either 13- or 20-nm-sized NPs (p = 0.04 and
p = 0.01, respectively). In addition, signiﬁcantly more
cytotoxicity (p = 0.05) was observed for 13 nm NPs
(70.1% ± 8.0%),comparedto20-nmNPs(44.0% ± 6.8%).
To further verify that cytotoxicity increases with decreasing
NP size, experiments were performed over a range of NP
concentrations. As shown in Fig. 7b, signiﬁcantly greater
toxicity was observed using 4-nm NPs compared to 20-nm
NP at all concentrations tested (p = 0.03 at 1 mM,
p = 0.0001 at 5 mM and p = 0.01 at 10 mM NP concen-
tration). In this paper, we have focused on the size-depen-
dence cytotoxicityofNPs.However,asshowninthe insetto
Fig. 2,theaspectratioofNPsincreaseswithsize.Therefore,
the role of shape morphology on NP cytotoxic response will
be the subject of future investigations.
To further evaluate the mechanism of nanotoxicity,
studies were performed to investigate the relationship
between size dependence and ZnO NP-induced ROS pro-
duction using PBMC cell cultures. Following a 3 h treat-
ment with different-sized ZnO NPs (4, 13 and 20 nm), a
size-dependent induction of ROS was observed at both NP
concentrations, with 4-nm-sized NPs consistently inducing
higher levels of ROS compared to 13- or 20-nm-sized NPs
(Fig. 8). At 5 mM NP concentrations, signiﬁcantly higher
levels of ROS were observed for 4 and 13-nm NPs
compared to 20-nm NPs (*4-fold relative increase (p =
0.005) and *3-fold increase (p = 0.01), respectively).
Similarly, 10 mM NP treatment resulted in signiﬁcant dif-
ferences in ROS production between all sizes of NP with a
3.2-fold greater induction of ROS observed between 4 and
20-nm NPs (p = 0.001), and a 1.9-fold increase observed
between 13 and 20-nm NPs (p = 0.0021). These ﬁndings
indicate that the generation of ROS is dependent on NP size.
The increased nanotoxicity with decreasing NP size may
be due in part to, the larger surface area/volume ratio of
smaller NPs, which provides them with a greater area to
associate with cellular membranes and proteins, as well as
greater surface reactivity. In addition, ZnO particles
Fig. 7 Effect of NP size on cytotoxicity. a Puriﬁed human CD4
? T
cells ([97% purity) were left untreated or incubated with different
sizes (4, 13, and 20 nm) of ZnO NPs at a ﬁnal concentration of 5 mM.
Following culture for 22–24 h, viability was determined using PI
uptake and ﬂow cytometry, n = 4. b Cytotoxicity studies in puriﬁed
human CD4
? T cells were performed using varying concentrations
(1–10 mM) of 4- and 20-nm-sized ZnO NPs, n = 4. Error bars depict
SE, and asterisks indicate statistically signiﬁcant differences
(p\0.05) as determined by repeated measures ANOVA
Fig. 8 Effects of NP size on ROS production in peripheral blood
immune cells. Primary human PBMC were treated with two different
concentrations of 8-nm-sized ZnO NPs (5 and 10 mM) for 3 h and
ROS production evaluated using a ﬂuorescent microplate reader. Data
from a representative experiment are shown (n = 3) with error bars
depicting SE. Data were analyzed using a 2-way ANOVA and
asterisks denote statistical signiﬁcance as deﬁned by p\0.05
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deﬁcient/zinc rich surface chemistries [10] that exhibit
strong electrostatic interactions with the negatively charged
cell membrane [35, 36], with smaller particles predicted to
have a greater positive surface charge to volume ratio.
Thus, greater initial cell membrane-NP association would
be expected for smaller NP, leading to potentially greater
intracellular uptake.
Following initial NP-cell electrostatic interactions,
mechanisms of toxicity likely proceed via the formation of
highly reactive oxygen species, such as hydrogen perox-
ide, hydroxyl radical, and superoxide anion [16]. The
ability of smaller-sized ZnO NPs to promote greater levels
of ROS may occur because as ZnO NP size decreases, so
does the nanocrystal quality, which results in increased
interstitial zinc ions and oxygen vacancies [37]. These
crystal defects lead to a large number of electron-hole
pairs (e
--h
?), which are typically activated by both UV
and visible light. However, for nanoscale ZnO, large
numbers of valence band holes and/or conduction band
electrons are thought to be available to serve in redox
reactions even in the absence of UV irradiation [17]. The
holes can split water molecules derived from the ZnO
suspension into H
? and OH
-. The resulting electrons react
with dissolved oxygen molecules to generate superoxide
radical anions (
•O2
-), which in turn react with H
? to
generate (HO2
•) radicals. These HO2
• molecules can then
produce hydrogen peroxide anions (HO2
-) following a
subsequent encounter with electrons. Hydrogen peroxide
anions can then react with hydrogen ions to produce
hydrogen peroxide (H2O2)[ 7, 38].
ZnO þ hv ! ZnO þ e  þ hþ; hþ þ H2O !  OH þ Hþ
e  þ O2 !  O 
2 ;  O 
2 þ Hþ ! HO 
2;
HO 
2 þ Hþ þ e  ! H2O2
All of the various ROS molecules produced in this fashion
can trigger redox-cycling cascades in the cell, or on adja-
cent cell membranes. This can then lead to the depletion of
endogenous cellular reserves of antioxidants such that
irreparable oxidative damage occurs to cellular biomole-
cules and eventually results in cell death.
ZnO NP Induce Proinﬂammatory Cytokine Production
in Primary Human Immune Cells
An important task of nanobiotechnology is to understand
the effect these nanomaterials have to modulate expression
of cytokines, which are soluble biological protein messen-
gers that regulate the immune system. Published studies
have demonstrated the ability of certain nanomaterials to
induce cytokine production, although this appears heavily
dependent on a variety of factors, including material com-
position, size, and method of delivery [39, 40]. Much
remains to be learned, however, regarding the pro-inﬂam-
matory potential of ZnO NPs. To address this gap in
knowledge, studies were performed to evaluate the ability
of ZnO NPs to modulate IFN-c, TNF-a, and IL-12 cytokine
production in primary human immune cells. These partic-
ular cytokines were chosen because they represent critical
pathways involved in the inﬂammatory response and dif-
ferentiation processes. Freshly isolated PBMC were treated
with varying concentrations of 8-nm ZnO NPs for 38 h, and
cell-free supernatants were used to quantify cytokine levels
using an ELISA. For IL-12 production, cell samples were
ﬁrst pretreated with IFN-c (1,000 U/mL) before addition of
NPs to provide a priming signal for IL-12 [41]. Results
demonstrate signiﬁcant dose-dependent increases in IFN-c
and TNF-a at all NP concentrations tested (0.05 mM,
0.1 mM and 0.2 mM) (Fig. 9). ZnO NPs had no effect on
IL-12 production in unprimed control cultures, but pre-
treatment with low level IFN-c prior to NP exposure
resulted in appreciable amounts of IL-12 in a concentration-
dependent manner. The inability of ZnO NPs to induce
IL-12 in resting cells was not altogether unexpected, as
expression of this cytokine typically occurs in cells that
have ﬁrst received a priming signal, such as IFN-c, which is
locally produced by other cells participating in the immune
response [41]. These results suggest that a synergistic
relationship between ZnO NPs and IFN-c may occur in in
Fig. 9 ZnO NPs increase proinﬂammatory cytokine production in
primary human peripheral blood cells. PBMC were left untreated or
treated with varying concentrations (0, 0.05, 0.1, and 0.2 mM) of 8-
nm ZnO NPs, both alone and with the addition of exogenous IFN-c
(1,000 U/mL), for 38 h. Cytokine production was evaluated by
ELISA and data analyzed using a 2-way ANOVA. Error bars
depicting SE, n = 3. Asterisks denote statistically signiﬁcant differ-
ences as deﬁned as p\0.05
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123vivo settings employing ZnO NPs, and demonstrate that
ZnO NPs are capable of inducing at least some key com-
ponents of inﬂammation.
The ability of ZnO NPs to induce proinﬂammatory
cytokine expression in human primary immune cells is
consistent with the recognized relationship between oxi-
dative stress and inﬂammation, which is partially mediated
by induction of the NF-jB transcription factor [42]. To
date, only limited studies have evaluated the effects of ZnO
NPs on cytokine production, and most of these studies have
been conducted in nonhematological cell types or in
immortalized cell lines, which frequently display altera-
tions in signal transduction pathways, leading to unpre-
dictable changes in protein expression. In one report, ZnO
NPs were shown to increase IL-8 and MCP-1 cytokine
mRNA expression in human aortic endothelial cells,
although no information was provided regarding changes in
corresponding protein levels [43]. In two other studies
conducted in immortalized rodent lung epithelial cells,
alveolar macrophage cell lines and primary alveolar mac-
rophages, ZnO NPs fail to induce TNF-a at concentrations
exceeding those used in this study [40, 44]. In addition, no
changes in other cytokines and chemokines including IL-6,
G-CSF, MIP-2, CXCL10, and CCL2 were detected. The
ability of ZnO NPs to induce high levels of TNF-a in our
studies may be due to differing responses observed
between cell populations studied (i.e., PBMC vs. alveolar
macrophages), or reﬂect the longer NP treatment exposure
period (i.e., 38 h vs. 24 h). Although, to the best of our
knowledge, no published studies have demonstrated the
ability of ZnO NPs to induce TNF-a or IL-6 production in
puriﬁed primary cell cultures or in toxicological evalua-
tions, it is interesting to note that inhalation of ultraﬁne
ZnO particles in occupational settings can increase the
expression of these cytokines, which is symptomatically
recognized as metal fume fever in welders (e.g., fatigue,
fever, chills, myalgias, cough, and leukocytosis) [16].
The ability of ZnO NPs to induce IL-12, IFN-c, and
TNF-a at NP concentrations below those causing appre-
ciable cytotoxicity indicates immunomodulatory effects
that may function to bias the immune response toward Th1-
mediated immunity. It is the cytokine proﬁle that directs
the development and differentiation of T helper cells into
the two different subsets, called type 1 (Th1) and type 2
(Th2) [45, 46]. Th1 cells are recognized to play an essential
role in promoting innate and cell-mediated immunity,
while Th2 cells promote antibody-based humoral responses
[45]. Relevant to our ﬁndings, IL-12 and IFN-c play critical
roles in Th1 development, and help set-up a perpetuating
loop whereby more Th1 development is favored, Th2
development is suppressed, and the cytotoxicity activity of
both NK cells and T cytotoxic cells against cancerous cells,
virally infected cells, or intracellular pathogens is enhanced
[46]. Thus, our ﬁndings indicate that careful titration of
ZnO NP-based therapeutic interventions may be successful
in elevating a group of cytokines important for eliciting a
Th1-mediated immune response with effective anti-cancer
actions. These results, combined with our previous obser-
vations demonstrating that immortalized hematopoietic
cancer cells are preferentially killed (*33-fold) by ZnO
NPs compared to normal cells of identical lineage [13],
suggest that ZnO NPs may function via a two-fold mech-
anism to eliminate cancer cells by direct and preferen-
tial cytotoxic actions, and by enhancing the type of
immunity most effective at eliciting an in vivo anti-cancer
response.
The ability of ZnO NPs to induce TNF-a may also help
to promote Th1 differentiation [45, 47] as well as func-
tioning as a regulator of acute inﬂammation [48]. Notably,
this cytokine received its name based on its potent in vitro
and in vivo anti-tumor activity. However, high level and/or
chronic exposure to TNF-a has been shown to produce
serious detrimental effects on the host, including septic
shock or symptoms associated with autoimmune disease
[48]. Our results demonstrate signiﬁcant dose-dependent
increases in TNF-a over a somewhat narrow range of ZnO
NP concentrations. The magnitude of TNF-a induction, as
well as other proinﬂammatory cytokines, and their local–
regional delivery to tumor sites or other desired areas, will
undoubtedly be important parameters when considering
ZnO NP for biomedical purposes to achieve the desired
therapeutic response without eliciting potential systemic
damaging effects from these cytokines.
Conclusions
Results from these studies demonstrate that ZnO NPs
induce toxicity in a cell-type speciﬁc manner that is
dependent on the degree of NP-cellular membrane associ-
ation, phagocytic ability, and inherent cellular capacities for
ROS production. Monocytic cells displayed the greatest
susceptibility and intracellular ROS production following
NP exposure, followed by NK cells, followed by lympho-
cytes, which displayed the most resistance. Studies
employing ROS quenchers implicate ROS formation as a
major mechanism of ZnO NP-induced toxicity, and dem-
onstrate that the generation of ROS and the cytotoxic proﬁle
occurs in a NP size-dependent manner, with smaller NPs
displaying the greatest effect. The variable responses of
immune cells described in this study underscore the need
for careful in vitro evaluation across a spectrum of relevant
cell types, followed by appropriate in vivo studies to pro-
vide useful and potentially predictive screening data
regarding the relative toxicity effects of metal-oxide NPs.
These factors are also important considerations for the
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123potential incorporation of ZnO NPs into novel nanotech-
nology-based biological applications.
Our results demonstrating that ZnO NPs can induce the
expression of immunoregulatory cytokines is also a rele-
vant consideration for potential use in biomedical appli-
cations, as many current treatments for human disease
function by manipulating and controlling components of
the immune response [49]. To the best of our knowledge,
our results appear to be the ﬁrst to document the ability of
ZnO NPs to increase the expression of IFN-c, TNF-a, and
IL-12 in primary immune human cells, and at NP con-
centrations below those causing appreciable cell death.
These ﬁndings suggest that ZnO NPs, when used at
appropriate concentrations, could directly enhance tumor
cell killing through the production of TNF-a, and could
also facilitate effective anti-cancer actions by eliciting a
cytokine proﬁle crucial for directing the development of
Th1-mediated immunity. The in vivo therapeutic window
for ZnO NP to increase proinﬂammatory cytokines indi-
cates that parameters controlling ZnO NP toxicity, such as
particle size, concentration, and biodistribution will need to
be carefully controlled when considering metal-oxide NPs
for use in biological applications, especially given the
recognized relationship of chronic inﬂammatory processes
and tumorigenesis. Future studies are needed to investigate
the effects of ZnO NPs on additional cytokines and
inﬂammatory mediators, as well as mechanisms of NP
cellular uptake and ROS formation.
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